Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Takeda Discontinues TAK-128 Clinical Program For Peripheral Diabetic Neuropathy

This article was originally published in PharmAsia News

Executive Summary

Takeda is discontinuing development of a Phase II compound, TAK-128, for the treatment of peripheral diabetic neuropathy after the candidate failed to show sufficient efficacy to support its continued development, the company reported

You may also be interested in...



Takeda Drops Phase II Diabetes Drug

Compound fails to measure up to exisiting treatments, firm says.

Takeda/BioNumerik’s Tavocept Phase III Data Did Not Meet Primary Endpoints

Takeda will consider terminating its licensing and development agreement for the investigational drug.

Takeda’s Combo Duetact Will Launch Later This Year For Type 2 Diabetes

Takeda's existing Actos sales force will detail the pioglitazone and glimepiride combination therapy to primary care physicians.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval

Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups

Investors Go Berserk For Viking, Putting It Top Of Q1 Winners

Sanofi Skates To Where The Puck Is With Immunology

See All
UsernamePublicRestriction

Register

SC065623

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By